UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting MAPK in recurrent, low-grade serous ovarian cancer

The Lancet (British edition), 2022-02, Vol.399 (10324), p.499-501

Blagden, Sarah P

2022

Volltextzugriff (PDF)

A source of hope for platinum-resistant ovarian cancer?

The Lancet (British edition), 2021-01, Vol.397 (10271), p.254-256

2021

Volltextzugriff (PDF)

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials

Clinical cancer research, 2022-06, Vol.28 (11), p.2201-2203

2022

Volltextzugriff (PDF)

Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer

Frontiers in oncology, 2015-06, Vol.5, p.149-149

Blagden, Sarah P

2015

Volltextzugriff (PDF)

Controversies around the function of LARP1

RNA biology, 2021-02, Vol.18 (2), p.207-217

2021

Volltextzugriff (PDF)

The biological and therapeutic relevance of mRNA translation in cancer

Nature reviews. Clinical oncology, 2011-05, Vol.8 (5), p.280-291

2011

Volltextzugriff (PDF)

The La-Related Proteins, a Family with Connections to Cancer

Biomolecules (Basel, Switzerland), 2015-10, Vol.5 (4), p.2701-2722

2015

Volltextzugriff (PDF)

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

eLife, 2017-04, Vol.6

2017

Volltextzugriff (PDF)

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

Nucleic acids research, 2016-02, Vol.44 (3), p.1227-1246

2016

Volltextzugriff (PDF)

From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit

The lancet oncology, 2023-04, Vol.24 (4), p.e150-e160

2023

Volltextzugriff (PDF)

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Cancers, 2022-03, Vol.14 (7), p.1621

2022

Volltextzugriff (PDF)

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Nature reviews. Cancer, 2015-11, Vol.15 (11), p.668-679

2015

Volltextzugriff (PDF)

Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells

Developmental cell, 2020-11, Vol.55 (3), p.298-313.e10

2020

Volltextzugriff (PDF)

Uptake of a new meningitis vaccination programme amongst first-year undergraduate students in the United Kingdom: A cross-sectional study

PloS one, 2017-08, Vol.12 (8), p.e0181817-e0181817

2017

Volltextzugriff (PDF)

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

British journal of cancer, 2019-05, Vol.120 (10), p.975-981

2019

Volltextzugriff (PDF)

Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development

Journal of medicinal chemistry, 2014-02, Vol.57 (4), p.1531-1542

2014

Volltextzugriff (PDF)

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Clinical cancer research, 2020-03, Vol.26 (5), p.1009-1016

2020

Volltextzugriff (PDF)

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

British journal of cancer, 2018-10, Vol.119 (7), p.815-822

2018

Volltextzugriff (PDF)

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

Clinical cancer research, 2021-12, Vol.27 (23), p.6500-6513

2021

Volltextzugriff (PDF)

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Clinical cancer research, 2019-03, Vol.25 (5), p.1472-1478

2019

Volltextzugriff (PDF)

A decade of LARP society

RNA biology, 2021-02, Vol.18 (2), p.157-158

2021

Volltextzugriff (PDF)

The perfect arrangement

Journal of clinical oncology, 2014-02, Vol.32 (6), p.601-602

Blagden, Sarah P

2014

Volltextzugriff (PDF)

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

BMC cancer, 2020-03, Vol.20 (1), p.198-5, Article 198

2020

Volltextzugriff (PDF)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

British journal of cancer, 2023-06, Vol.128 (12), p.2227-2235

2023

Volltextzugriff (PDF)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e004235

2022

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Englisch
(163)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeting MAPK in recurrent, low-grade serous ovarian cancer

A source of hope for platinum-resistant ovarian cancer?

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials

Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer

Controversies around the function of LARP1

The biological and therapeutic relevance of mRNA translation in cancer

The La-Related Proteins, a Family with Connections to Cancer

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells

Uptake of a new meningitis vaccination programme amongst first-year undergraduate students in the United Kingdom: A cross-sectional study

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

A decade of LARP society

The perfect arrangement

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Suchergebnisse filtern